Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Management of refractory venous thrombosis associated with malignancy using a supra-therapeutic enoxaparin regimen.

Cunningham MS, Gilmore R, O'Donnell D, O'Donnell JS.

Ir J Med Sci. 2009 Sep;178(3):339-41. doi: 10.1007/s11845-008-0200-9. Epub 2008 Aug 27.

PMID:
18751756
2.

Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.

Nutescu EA.

Am J Health Syst Pharm. 2007 Jun 1;64(11 Suppl 7):S5-13. Review.

PMID:
17519445
3.

Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia.

Imberti D, Vallisa D, Anselmi E, Moroni CF, Bertè R, Lazzaro A, Bernuzzi P, Arcari AL, Cavanna L.

Tumori. 2004 Jul-Aug;90(4):390-3.

PMID:
15510981
4.

Venous thromboembolism in cancer patients: expanding horizons.

Bergqvist D.

Semin Thromb Hemost. 2002 Aug;28 Suppl 3:19-23. Review.

PMID:
12232819
5.

Treatment of DVT: how long is enough and how do you predict recurrence.

Agnelli G, Becattini C.

J Thromb Thrombolysis. 2008 Feb;25(1):37-44. Epub 2007 Oct 1. Review.

PMID:
17906973
6.

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.

van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.

Thromb Haemost. 2009 Apr;101(4):762-9.

PMID:
19350123
7.

Emerging options in the treatment of venous thromboembolism.

Nutescu EA.

Am J Health Syst Pharm. 2004 Dec 1;61(23 Suppl 7):S12-7. Review.

PMID:
15597574
8.

Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.

Harenberg J, Jörg I, Weiss C.

Eur J Clin Pharmacol. 2006 Mar;62(3):173-7. Epub 2006 Jan 14.

PMID:
16416154
9.

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY.

J Thromb Haemost. 2009 May;7(5):760-5. doi: 10.1111/j.1538-7836.2009.03326.x. Epub 2009 Feb 24.

10.

[Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].

Heidenreich C, Hohmann V, Bramlage P.

Med Klin (Munich). 2009 Jan 15;104(1):20-7. doi: 10.1007/s00063-009-1004-z. Epub 2009 Jan 14. German.

PMID:
19142593
11.

A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency.

Tai CY, Ierardi R, Alexander JB.

Ann Vasc Surg. 2004 Mar;18(2):237-42.

PMID:
15253263
12.

Overview of enoxaparin in the treatment of deep vein thrombosis.

Deitcher SR.

Am J Manag Care. 2000 Nov;6(20 Suppl):S1026-33. Review.

14.

Oral anticoagulant therapy in venous thromboembolism.

Cosmi B, Palareti G.

Semin Vasc Med. 2003 Aug;3(3):303-14. Review.

PMID:
15199464
15.

Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.

Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, Mayzell G, Spyropoulos AC.

Clin Ther. 2004 Jul;26(7):1149-59.

PMID:
15336480
16.

[Treatment of venous thromboembolic disease in cancer patients].

Farge-Bancel D, Florea L, Bosquet L, Debourdeau P.

Pathol Biol (Paris). 2008 Jun;56(4):220-8. doi: 10.1016/j.patbio.2008.02.007. Epub 2008 Apr 3. Review. French.

PMID:
18394821
17.

Low molecular weight heparins: a guide to their optimum use in pregnancy.

Laurent P, Dussarat GV, Bonal J, Jego C, Talard P, Bouchiat C, Cellarier G.

Drugs. 2002;62(3):463-77. Review. Erratum in: Drugs 2002;62(9):1314.

PMID:
11827560
18.

Current management of acute symptomatic deep vein thrombosis.

Heit JA.

Am J Cardiovasc Drugs. 2001;1(1):45-50. Review.

PMID:
14728051
19.
20.

Venous thrombosis in cancer patients: insights from the FRONTLINE survey.

Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J.

Oncologist. 2003;8(4):381-8.

Supplemental Content

Support Center